Skip to main content
NIH funding notice PAR-17-193

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01)

Closed on May 7, 2020.

Posted
March 29, 2017
Close date
May 7, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,415,278 in first-year total cost, median $707,639.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 ETTN-G (50)]1
  2. Special Emphasis Panel[ZRG1 MDCN-C (50)]1

Most frequent institutions

  1. STANFORD UNIVERSITY1
  2. UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON1
Competing awards under PAR-17-193 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2021Theranostics for Pediatric Brain Cancer1R01HD103638-01DALDRUP-LINK, HEIKE ELIZABETHSTANFORD UNIVERSITY, CA$676,775ZRG1
2019Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology1R01HD099543-01SIRIANNI, RACHAEL WUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX$738,503ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-17-193: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01) | ScienceDex | ConductScience